NCT00287885

Who might be able to join this trial:

• You have been diagnosed with an advanced gynecological cancer (such as ovarian, cervical, or uterine cancer) that has been confirmed by a tissue sample (biopsy), and the cancer has not responded well to previous treatments.
• You have already received chemotherapy, and your cancer has either come back or did not fully go away after treatment.
• You have at least one area of cancer that can be measured on a scan, OR you have cancer that shows up on blood tests (a protein called CA-125 is above 50 units/ml on two tests taken at least one week apart).
• You are generally well enough to carry out light activity and care for yourself (your doctor will assess this using a standard scale called ECOG, and you need to score 0 or 1).
• You are at least 18 years old.
• Your blood, liver, and kidney test results are within acceptable ranges, checked within the past 4 weeks before joining.
• You have not had another cancer in the past 5 years, except for certain minor skin cancers or a very early-stage cervical condition.
• You have not received hormonal or immune therapy in the last 2 weeks, or chemotherapy/radiation in the last 4 weeks (some specific drugs require a 6-week gap — confirm with trial site).
• You are willing and able to sign a written consent form confirming you understand the experimental nature of the treatment and its possible risks.

Who may not be able to join:

• You are currently pregnant or breastfeeding, as the study drugs could be harmful to an unborn baby or infant.
• You are able to become pregnant but are unwilling to use reliable contraception (preferably a barrier method such as condoms) during the trial.
• You have a history of a heart attack, heart failure, or significant heart valve or blood flow problems in the heart.
• You have cancer that has spread to the brain.
• You have moderate to severe nerve damage in your hands or feet (such as numbness, tingling, or pain — confirm level with trial site).
• You have previously had a serious allergic reaction to docetaxel (a chemotherapy drug) or to certain other medicines containing a substance called polysorbate 80.

Important: Always verify eligibility with the trial site directly before applying.